Over 30,000 patients treated with Versius
Over 30,000 patients treated with Versius Versius—the second most utilised soft tissue surgical robot in the worldi—has now ...
CMR Surgical: Over 30,000 patients treated with Versius
Over 30,000 patients treated with Versius Versius-the second most utilised soft tissue surgical robot in the worldi-has now been used in over 30,000 surgical cases globally across a broad range of ...
Pune: India’s First Urological Reconstruction Surgery Restores Woman’s Life, Enables Motherhood
The first surgery was conducted in April 2022, in which a new urinary tract was reconstructed using vaginal tissue, restoring ...
medtechdive13h
Medtronic nears FDA submission for Hugo robot
CEO Geoff Martha said Medtronic would submit its application for urological procedures to the Food and Drug Administration by ...
Too Old to Operate17h
Risk Factors and Survival After Nephrectomy and Thrombectomy in RCC
The following is a summary of “Risk factors for renal insufficiency and survival implications after radical nephrectomy and ...
Santa Barbara Independent11h
Outpatient Surgery Center at Sutter Health Greater Central Coast One of the First in the Country to Acquire a da Vinci 5® Robotic Surgical System
Press releases are posted on Independent.com as a free community service.
Medtronic stock moves lower amid declines in surgical stapler business
The massive robot-making, pacemaker-inventing medtech company Medtronic is facing a financial snag: the humble stapler.
The Express Tribune11h
'Vessel sealing system' installed at ATH
The Ayub Teaching Hospital (ATH) has taken another step towards enhancing medical facilities with the installation of the ...
MassDevice10h
Medtronic slightly misses on revenue in Q3
Medtronic stock was down stock was down today after its third-quarter revenue slightly missed the Wall Street analyst consensus.
Le Lézard19h
Kiromic BioPharma Reports Patient 4 in Deltacel-01 Clinical Trial Reaches 10-Month Progression-Free Survival
Kiromic BioPharma, Inc. ("Kiromic" or the "Company") reports continued favorable efficacy results from the 10-month follow-up visit for the fourth patient enrolled in its Deltacel-01 Phase 1 clinical ...
Teleflex to Present at the Raymond James & Associates 46th Annual Institutional Investors Conference
WAYNE, Pa., Feb. 18, 2025 (GLOBE NEWSWIRE) -- Management of Teleflex Incorporated (NYSE: TFX), will be presenting at the Raymond James & Associates 46th Annual Institutional Investors Conference at ...